Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
VNDA's Cash to Debt is ranked higher than
85% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. VNDA: No Debt )
VNDA' s 10-Year Cash to Debt Range
Min: 209.57   Max: No Debt
Current: No Debt

Equity to Asset 0.01
VNDA's Equity to Asset is ranked higher than
52% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. VNDA: 0.01 )
VNDA' s 10-Year Equity to Asset Range
Min: 0.01   Max: 0.32
Current: 0.01

0.01
0.32
Interest Coverage No Debt
VNDA's Interest Coverage is ranked higher than
69% of the 577 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. VNDA: No Debt )
VNDA' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: -4.57
M-Score: -0.04
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -131.51
VNDA's Operating margin (%) is ranked higher than
70% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. VNDA: -131.51 )
VNDA' s 10-Year Operating margin (%) Range
Min: -28023.53   Max: 24.75
Current: -131.51

-28023.53
24.75
Net-margin (%) -131.18
VNDA's Net-margin (%) is ranked higher than
70% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. VNDA: -131.18 )
VNDA' s 10-Year Net-margin (%) Range
Min: -27864.71   Max: 20.14
Current: -131.18

-27864.71
20.14
ROE (%) -244.14
VNDA's ROE (%) is ranked higher than
52% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. VNDA: -244.14 )
VNDA' s 10-Year ROE (%) Range
Min: -221.21   Max: 23.67
Current: -244.14

-221.21
23.67
ROA (%) -48.87
VNDA's ROA (%) is ranked higher than
64% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. VNDA: -48.87 )
VNDA' s 10-Year ROA (%) Range
Min: -176.39   Max: 3.28
Current: -48.87

-176.39
3.28
ROC (Joel Greenblatt) (%) -2591.07
VNDA's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. VNDA: -2591.07 )
VNDA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4993.01   Max: 784.55
Current: -2591.07

-4993.01
784.55
Revenue Growth (3Y)(%) -3.60
VNDA's Revenue Growth (3Y)(%) is ranked higher than
75% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. VNDA: -3.60 )
VNDA' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 89.7
Current: -3.6

0
89.7
» VNDA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

VNDA Guru Trades in Q4 2013

Steven Cohen Sold Out
Jim Simons Sold Out
» More
Q1 2014

VNDA Guru Trades in Q1 2014

John Paulson 1,392,500 sh (New)
» More
Q2 2014

VNDA Guru Trades in Q2 2014

John Paulson 3,200,000 sh (+129.8%)
» More
Q3 2014

VNDA Guru Trades in Q3 2014

John Paulson 3,250,000 sh (+1.56%)
» More
» Details

Insider Trades

Latest Guru Trades with VNDA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2014-06-30 Add 129.8%0.12%$9.7 - $16.96 $ 12.25-8%3200000
John Paulson 2014-03-31 New Buy0.11%$10.5 - $18.71 $ 12.25-13%1392500
Jean-Marie Eveillard 2013-09-30 Sold Out 0.02%$8.05 - $13.031 $ 12.2514%0
Jean-Marie Eveillard 2013-06-30 Reduce -48.99%0.01%$3.93 - $13 $ 12.2582%975000
Jean-Marie Eveillard 2012-12-31 Add 43.16%0.01%$3.03 - $4.16 $ 12.25246%1911452
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Vanda Pharmaceuticals Inc

John Paulson's 4 Stocks Trading for Less Than He Paid for Them
John Paulson (Trades, Portfolio)’s firm Paulson & Co. manages approximately $21.4 billion and focuses specifically on arbitrage strategies, restructurings and other capital events. When his team analyzes stocks undergoing corporate events or sectors in which they have interest, they employ a bottom-up assessment of fundamentals within those targets. Read more...

Ratios

vs
industry
vs
history
P/B 408.33
VNDA's P/B is ranked higher than
56% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. VNDA: 408.33 )
VNDA' s 10-Year P/B Range
Min: 3.56   Max: 540.33
Current: 408.33

3.56
540.33
P/S 9.50
VNDA's P/S is ranked higher than
82% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. VNDA: 9.50 )
VNDA' s 10-Year P/S Range
Min: 2.62   Max: 69.06
Current: 9.5

2.62
69.06
EV-to-EBIT -6.27
VNDA's EV-to-EBIT is ranked higher than
81% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. VNDA: -6.27 )
VNDA' s 10-Year EV-to-EBIT Range
Min: -1244.2   Max: 558.3
Current: -6.27

-1244.2
558.3
Current Ratio 1.67
VNDA's Current Ratio is ranked higher than
57% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. VNDA: 1.67 )
VNDA' s 10-Year Current Ratio Range
Min: 1.67   Max: 18.62
Current: 1.67

1.67
18.62
Quick Ratio 1.64
VNDA's Quick Ratio is ranked higher than
59% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. VNDA: 1.64 )
VNDA' s 10-Year Quick Ratio Range
Min: 1.64   Max: 18.62
Current: 1.64

1.64
18.62

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.36
VNDA's Price/Median PS Value is ranked higher than
79% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. VNDA: 1.36 )
VNDA' s 10-Year Price/Median PS Value Range
Min: 0.46   Max: 9.45
Current: 1.36

0.46
9.45
Earnings Yield (Greenblatt) -15.90
VNDA's Earnings Yield (Greenblatt) is ranked higher than
62% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. VNDA: -15.90 )
VNDA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 3521.3
Current: -15.9

0.2
3521.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:VM4.Germany,
Vanda Pharmaceuticals, Inc. was incorporated in Delaware in 2002 and began operations in March 2003. The Company is a biopharmaceutical company engaged in the development and commercialization of products for the treatment of central nervous system disorders. It operates in one business segment which is the development and commercialization of pharmaceutical products. Its product portfolio includes: HETLIOZ, a product for the treatment of Non-24-Hour Sleep-Wake Disorder, which was approved by the U.S. FDA in January 2014; Fanapt, a product for the treatment of schizophrenia, the oral formulation of which is currently being marketed and sold in the U.S. by Novartis Pharma AG; and VLY-686, a small molecule neurokinin-1 receptor antagonist. The Company utilizes a virtual supply manufacturing and distribution chain in which it does not have its own facilities to manufacture commercial or clinical trial supplies of drugs and does not have its own distribution facilities.
» More Articles for VNDA

Headlines

Articles On GuruFocus.com
John Paulson's Stocks Trading for Less Than He Paid for Them Jun 02 2014 
Best Performing Gurus of Past Six Months are John Paulson, First Eagle and Michael Price Jun 11 2013 
comment on VNDA Nov 12 2012 
Vanda: This Company Has Great Assets But No Profits Jan 21 2012 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
$VNDA New study started: Oct 15 2010 
Hourly trend UP Aug 11 2010 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
upgraded to BUY Jul 07 2010 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) May 10 2010 

More From Other Websites
Nasdaq stocks posting largest percentage increases Dec 19 2014
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers Dec 05 2014
Vanda Pharmaceuticals to Present at the 26th Annual Piper Jaffray Healthcare Conference Dec 01 2014
Vanda Pharmaceuticals to Present at the 26th Annual Piper Jaffray Healthcare Conference Dec 01 2014
Idera Pharmaceuticals Names Vincent J. Milano Chief Executive Officer Dec 01 2014
Idera Pharmaceuticals Names Vincent J. Milano Chief Executive Officer Dec 01 2014
Vanda Pharmaceuticals to Present at the Stifel Nicolaus 2014 Healthcare Conference Nov 18 2014
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Other Events Nov 03 2014
VANDA PHARMACEUTICALS INC. Financials Oct 31 2014
10-Q for Vanda Pharmaceuticals, Inc. Oct 29 2014
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Oct 29 2014
Vanda Pharmaceuticals Inc. Prices Public Offering of Common Stock Oct 29 2014
Vanda Pharmaceuticals Inc. Prices Public Offering of Common Stock Oct 29 2014
Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock Oct 28 2014
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 28 2014
Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock Oct 28 2014
Twitter Takes A Tumble As Ability To Innovate Comes Into Question Oct 28 2014
S&P 500 trades in a narrow range, up against key technical levels Oct 27 2014
Vanda Pharmaceuticals Inc Earnings Call scheduled for 10:00 am ET today Oct 27 2014
Vanda Pharmaceuticals Reports Third Quarter 2014 Financial Results Oct 27 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK